{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:20:22Z","timestamp":1772832022547,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Backgrounds:<\/jats:bold> Proteasome inhibitors (PI) cause toxic peripheral neuropathy (PN), which is one of the dose-limiting adverse events of these treatments. Recent preclinical studies find that factor Xa inhibitor (FXaI), rivaroxaban, promotes PN in animals receiving oxaliplatin. Cancer patients can receive combined therapy of PI and FXaI. This study aimed to identify and characterize the interaction signals for the concomitant use of PI and FXaI resulting in PN.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Reports from the United States FDA Adverse Event Reporting System (FAERS) were extracted from the first quarter of 2004 to the first quarter of 2020 for analysis. The Standardized Medical Dictionary for Regulatory Activities (MedDRA) query was used to identify PN cases. We conducted an initial disproportionality investigation to detect PN adverse event signals associated with the combined use of PI and FXaI by estimating a reporting odds ratio (ROR) with a 95% confidence interval (CI). The adjusted RORs were then analyzed by logistic regression analysis (adjusting for age, gender, and reporting year), and additive\/multiplicative models were performed to further confirm the findings. Additionally, subset data analysis was performed on the basis of a single drug of PI and FXaI.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 159,317 adverse event reports (including 2,822\u00a0PN reports) were included. The combined use of PI and FXaI was associated with a higher reporting of PN (RORadj = 7.890, 95%CI, 5.321\u201311.698). The result remained significant based on additive\/multiplicative methods. The observed association was consistent in the analysis restricted to all specific PI agents (bortezomib and ixazomib) and FXaI (rivaroxaban), except apixaban.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Analysis of FAERS data identified reporting associations of PN in the combined use of PI and FXaI, suggesting the need for more robust preclinical and clinical studies to elucidate the relationship.<\/jats:p>","DOI":"10.3389\/fphar.2022.757415","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:25:09Z","timestamp":1647235509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions"],"prefix":"10.3389","volume":"13","author":[{"given":"Long","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00592-019-01378-7","article-title":"Myopathy with DPP-4 Inhibitors and Statins in the Real World: Investigating the Likelihood of Drug-Drug Interactions through the FDA Adverse Event Reporting System","volume":"57","author":"Antonazzo","year":"2020","journal-title":"Acta Diabetol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced Peripheral Neurotoxicity (CIPN): an Update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based Drug Repurposing: The Search for Inverse Signals via OpenVigil Identifies Putative Drugs against Viral Respiratory Infections","volume":"81","author":"B\u00f6hm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free Eyeballs on AERS Pharmacovigilance Data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PloS one"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e006058","DOI":"10.1161\/CIRCOUTCOMES.119.006058","article-title":"Rivaroxaban versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort","volume":"13","author":"Bonde","year":"2020","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral Neuropathy during Bortezomib Treatment of Multiple Myeloma: a Review of Recent Studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/s0959-8049(02)00229-0","article-title":"Current Status and Future Prospects for the Treatment of Chemotherapy-Induced Peripheral Neurotoxicity","volume":"38","author":"Cavaletti","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: an Analysis of the FDA Adverse Event Reporting System Database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 International Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Patients with Cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and Safety of Apixaban Compared with Rivaroxaban for Patients with Atrial Fibrillation in Routine Practice: A Cohort Study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejphar.2018.03.022","article-title":"Mechanism of Cardiovascular Toxicity by Proteasome Inhibitors: New Paradigm Derived from Clinical and Pre-clinical Evidence","volume":"828","author":"Gavazzoni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","article-title":"Adverse Event Profiles of Dipeptidyl Peptidase-4 Inhibitors: Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"21","author":"Huang","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System","volume":"10","author":"Huang","year":"2020","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous Thromboembolism and Prognosis in Cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00280-020-04135-8","article-title":"A Placebo-Controlled, Double-Blind, Randomized Study of Recombinant Thrombomodulin (ART-123) to Prevent Oxaliplatin-Induced Peripheral Neuropathy","volume":"86","author":"Kotaka","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in Multiple Myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematol. Am Soc Hematol Educ Program"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-020-02354-7","article-title":"Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma: where Are We and where Are We Going?","volume":"52","author":"Lapietra","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety Evaluation of Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.594043","article-title":"Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database","volume":"8","author":"Meng","year":"2021","journal-title":"Front. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can Disproportionality Analysis of post-marketing Case Reports Be Used for Comparison of Drug Safety Profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jphs.2021.03.001","article-title":"Estrogen Decline Is a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy: Clinical Evidence Supported by a Preclinical Study","volume":"146","author":"Miyamoto","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced Neuropathy and its Association with Quality of Life Among 2- to 11-year Colorectal Cancer Survivors: Results from the Population-Based PROFILES Registry","volume":"31","author":"Mols","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with Non-small Cell Lung Cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","article-title":"New Oral Anticoagulants: a Review of the Literature with Particular Emphasis on Patients with Impaired Renal Function","volume":"72","author":"Poulsen","year":"2012","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.2217\/fon-2019-0429","article-title":"Third- and Later-Line Treatment in Advanced or Metastatic Gastric Cancer: a Systematic Review and Meta-Analysis","volume":"16","author":"Rizzo","year":"2020","journal-title":"Future Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel Proteasome Inhibitors to Overcome Bortezomib Resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"B32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14740338.2017.1259310","article-title":"Safety of Proteasome Inhibitors for Treatment of Multiple Myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuropharm.2018.08.040","article-title":"Paclitaxel-induced HMGB1 Release from Macrophages and its Implication for Peripheral Neuropathy in Mice: Evidence for a Neuroimmune Crosstalk","volume":"141","author":"Sekiguchi","year":"2018","journal-title":"Neuropharmacology"},{"key":"B34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/ijms22010367","article-title":"Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy","volume":"22","author":"Sekiguchi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous Thromboembolism in Multiple Myeloma - Choice of Prophylaxis, Role of Direct Oral Anticoagulants and Special Considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12974-019-1581-6","article-title":"Role of Non-macrophage Cell-Derived HMGB1 in Oxaliplatin-Induced Peripheral Neuropathy and its Prevention by the Thrombin\/thrombomodulin System in Rodents: Negative Impact of Anticoagulants","volume":"16","author":"Tsubota","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.3390\/cells10102550","article-title":"Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice","volume":"10","author":"Tsubota","year":"2021","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bph.15091","article-title":"Role of High-Mobility Group Box 1 and its Modulation by Thrombomodulin\/thrombin axis in Neuropathic and Inflammatory Pain","volume":"178","author":"Tsujita","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting Drug-Drug Interactions Using a Database for Spontaneous Adverse Drug Reactions: an Example with Diuretics and Non-steroidal Anti-inflammatory Drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","article-title":"Signalling Possible Drug-Drug Interactions in a Spontaneous Reporting System: Delay of Withdrawal Bleeding during Concomitant Use of Oral Contraceptives and Itraconazole","volume":"47","author":"van Puijenbroek","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","article-title":"Neurological Monitoring Reduces the Incidence of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients","volume":"15","author":"Velasco","year":"2010","journal-title":"J. Peripher. Nerv Syst."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/pds.3626","article-title":"Acute Kidney Injury during Concomitant Use of Valacyclovir and Loxoprofen: Detecting Drug-Drug Interactions in a Spontaneous Reporting System","volume":"23","author":"Yue","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","article-title":"Genetic Polymorphisms in Candidate Genes Are Not Associated with Increased Vincristine-Related Peripheral Neuropathy in Arab Children Treated for Acute Childhood Leukemia: a Single Institution Study","volume":"28","author":"Zgheib","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/psp4.12267","article-title":"Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research","volume":"7","author":"Zhang","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.757415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:25:13Z","timestamp":1647235513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.757415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":45,"alternative-id":["10.3389\/fphar.2022.757415"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.757415","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"article-number":"757415"}}